Market Cap 1.86B
Revenue (ttm) 1.18B
Net Income (ttm) 2.05M
EPS (ttm) N/A
PE Ratio 50.19
Forward PE 42.56
Profit Margin 0.17%
Debt to Equity Ratio 0.00
Volume 722,100
Avg Vol 679,778
Day's Range N/A - N/A
Shares Out 44.88M
Stochastic %K 90%
Beta 0.78
Analysts Strong Sell
Price Target $57.43

Company Profile

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care...

Industry: Health Information Services
Sector: Healthcare
Phone: 877 415 9990
Address:
4220 North Freeway, Suite 301, Fort Worth, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 9:58 PM
$OMCL RSI: 37.96, MACD: -1.8222 Vol: 4.74, MA20: 41.31, MA50: 45.24 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 12:25 AM
$OMCL Current Stock Price: $38.62 Contracts to trade: $40.0 OMCL Feb 20 2026 Call Entry: $0.07 Exit: $0.11 ROI: 57% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 16 at 5:43 PM
$OMCL Share Price: $36.49 Contract Selected: Aug 21, 2026 $35 Calls Buy Zone: $4.59 – $5.67 Target Zone: $8.63 – $10.54 Potential Upside: 78% ROI Time to Expiration: 185 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 5 at 11:39 AM
$OMCL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.05 down -114.71% YoY • Reported revenue of $313.98M up 2.32% YoY • Omnicell expects 2026 total revenues to range from $1.22B to $1.26B, with Non-GAAP EBITDA projected between $145M and $160M, and Non-GAAP EPS between $1.65 and $1.85.
0 · Reply
IN0V8
IN0V8 Feb. 4 at 7:47 PM
$OMCL Buy BofA Global Research raises price objective to $70 from $53 BofA Global Research raises to buy from neutral
0 · Reply
FowleyOsseltonk
FowleyOsseltonk Feb. 4 at 6:35 PM
BofA Securities upgraded $OMCL to Buy from Neutral and raised its price target to $70 from $53. The call is driven by expectations of an upside revision cycle from the launch of Omnicell’s new Titan XT automated dispensing cabinet, its first major cabinet refresh since 2017. BofA notes the Street is modeling only 3–4% connected-device revenue CAGR through 2028, versus mid-teens growth in the prior cycle. Shares trade at <13x near-trough 2026 EBITDA versus a 10-year average of ~16x. BofA’s 2027/2028 revenue and EBITDA estimates are 8% and 23% above consensus. While 2026 is seen as a transition year and initial guidance may be conservative, BofA views any weakness as a buying opportunity.
0 · Reply
MagnetarMarkets
MagnetarMarkets Feb. 4 at 10:04 AM
$OMCL healthcare software, medication management
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 1:59 PM
$OMCL RSI: 65.98, MACD: 1.9942 Vol: 2.29, MA20: 48.90, MA50: 43.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SeanDavid
SeanDavid Jan. 24 at 10:06 PM
Give this new ETF a follow if you are in any of the names below. $AVRY $OMCL $Z $YOU $MNDY
0 · Reply
topstockalerts
topstockalerts Jan. 13 at 2:23 PM
$OMCL following closely 👀
0 · Reply
Latest News on OMCL
Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript

Feb 5, 2026, 7:24 PM EST - 21 days ago

Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript


Omnicell, Inc. (OMCL) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 3:36 PM EDT - 4 months ago

Omnicell, Inc. (OMCL) Q3 2025 Earnings Call Transcript


Omnicell Announces Third Quarter 2025 Financial Results

Oct 30, 2025, 6:30 AM EDT - 4 months ago

Omnicell Announces Third Quarter 2025 Financial Results


Omnicell Q2 Earnings: Market Ignoring The Segments

Jul 31, 2025, 11:45 AM EDT - 7 months ago

Omnicell Q2 Earnings: Market Ignoring The Segments


Omnicell Announces Second Quarter 2025 Results

Jul 31, 2025, 6:30 AM EDT - 7 months ago

Omnicell Announces Second Quarter 2025 Results


Omnicell Opens New Innovation Lab in Austin, Texas

May 14, 2025, 8:30 AM EDT - 10 months ago

Omnicell Opens New Innovation Lab in Austin, Texas


Omnicell: Facing New Headwinds

May 7, 2025, 1:25 PM EDT - 10 months ago

Omnicell: Facing New Headwinds


Omnicell, Inc. (OMCL) Q1 2025 Earnings Conference Call Transcript

May 6, 2025, 12:28 PM EDT - 10 months ago

Omnicell, Inc. (OMCL) Q1 2025 Earnings Conference Call Transcript


Omnicell Announces First Quarter 2025 Results

May 6, 2025, 6:30 AM EDT - 10 months ago

Omnicell Announces First Quarter 2025 Results


Omnicell Announces Chief Financial Officer Transition

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Omnicell Announces Chief Financial Officer Transition


Omnicell Q4 Earnings: Ignore The Short-Term Noise

Feb 12, 2025, 7:44 AM EST - 1 year ago

Omnicell Q4 Earnings: Ignore The Short-Term Noise


Omnicell, Inc. (OMCL) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 1:24 PM EST - 1 year ago

Omnicell, Inc. (OMCL) Q4 2024 Earnings Call Transcript


Omnicell Announces OmniSphere

Dec 9, 2024, 8:30 AM EST - 1 year ago

Omnicell Announces OmniSphere


Omnicell Q3 Earnings: Look At The Growth Segment

Nov 1, 2024, 11:58 AM EDT - 1 year ago

Omnicell Q3 Earnings: Look At The Growth Segment


Omnicell, Inc. (OMCL) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 2:07 PM EDT - 1 year ago

Omnicell, Inc. (OMCL) Q3 2024 Earnings Call Transcript


Omnicell Announces Third Quarter 2024 Results

Oct 30, 2024, 6:30 AM EDT - 1 year ago

Omnicell Announces Third Quarter 2024 Results


Omnicell Announces Central Med Automation Service

Aug 20, 2024, 4:30 PM EDT - 1 year ago

Omnicell Announces Central Med Automation Service


Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript

Aug 4, 2024, 1:49 AM EDT - 1 year ago

Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript


Omnicell Announces Second Quarter 2024 Results

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Omnicell Announces Second Quarter 2024 Results


Omnicell, Inc. (OMCL) Q1 2024 Earnings Call Transcript

May 2, 2024, 2:22 PM EDT - 1 year ago

Omnicell, Inc. (OMCL) Q1 2024 Earnings Call Transcript


Omnicell Announces First Quarter 2024 Results

May 2, 2024, 7:30 AM EDT - 1 year ago

Omnicell Announces First Quarter 2024 Results


Omnicell Announces XT Amplify

Apr 16, 2024, 4:01 PM EDT - 2 years ago

Omnicell Announces XT Amplify


OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 9:58 PM
$OMCL RSI: 37.96, MACD: -1.8222 Vol: 4.74, MA20: 41.31, MA50: 45.24 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 12:25 AM
$OMCL Current Stock Price: $38.62 Contracts to trade: $40.0 OMCL Feb 20 2026 Call Entry: $0.07 Exit: $0.11 ROI: 57% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 16 at 5:43 PM
$OMCL Share Price: $36.49 Contract Selected: Aug 21, 2026 $35 Calls Buy Zone: $4.59 – $5.67 Target Zone: $8.63 – $10.54 Potential Upside: 78% ROI Time to Expiration: 185 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 5 at 11:39 AM
$OMCL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.05 down -114.71% YoY • Reported revenue of $313.98M up 2.32% YoY • Omnicell expects 2026 total revenues to range from $1.22B to $1.26B, with Non-GAAP EBITDA projected between $145M and $160M, and Non-GAAP EPS between $1.65 and $1.85.
0 · Reply
IN0V8
IN0V8 Feb. 4 at 7:47 PM
$OMCL Buy BofA Global Research raises price objective to $70 from $53 BofA Global Research raises to buy from neutral
0 · Reply
FowleyOsseltonk
FowleyOsseltonk Feb. 4 at 6:35 PM
BofA Securities upgraded $OMCL to Buy from Neutral and raised its price target to $70 from $53. The call is driven by expectations of an upside revision cycle from the launch of Omnicell’s new Titan XT automated dispensing cabinet, its first major cabinet refresh since 2017. BofA notes the Street is modeling only 3–4% connected-device revenue CAGR through 2028, versus mid-teens growth in the prior cycle. Shares trade at <13x near-trough 2026 EBITDA versus a 10-year average of ~16x. BofA’s 2027/2028 revenue and EBITDA estimates are 8% and 23% above consensus. While 2026 is seen as a transition year and initial guidance may be conservative, BofA views any weakness as a buying opportunity.
0 · Reply
MagnetarMarkets
MagnetarMarkets Feb. 4 at 10:04 AM
$OMCL healthcare software, medication management
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 1:59 PM
$OMCL RSI: 65.98, MACD: 1.9942 Vol: 2.29, MA20: 48.90, MA50: 43.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SeanDavid
SeanDavid Jan. 24 at 10:06 PM
Give this new ETF a follow if you are in any of the names below. $AVRY $OMCL $Z $YOU $MNDY
0 · Reply
topstockalerts
topstockalerts Jan. 13 at 2:23 PM
$OMCL following closely 👀
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 8 at 6:39 PM
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 30 at 1:23 AM
$OMCL RSI: 65.58, MACD: 2.5776 Vol: 2.98, MA20: 43.49, MA50: 37.74 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Dec. 9 at 2:51 PM
Benchmark maintains Omnicell $OMCL at Buy and raises the price target from $45 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 1:12 PM
Benchmark updates rating for Omnicell ( $OMCL ) to Buy, target set at 45 → 50.
0 · Reply
Buymyshares
Buymyshares Dec. 9 at 6:48 AM
$OMCL @SeanDavid Sorry but this is just marketing bullshit. Small software evolution pumped up by the product organisation. The XT is still an old designed machine, manufactured in the Milpitas obsolete and expensive factory.... Omnicell is lacking real innovation and new products vs competition and the long term investors know it - look at the share trends in the last 2 years...
1 · Reply
SeanDavid
SeanDavid Dec. 9 at 12:24 AM
Big news for Omnicell today. Titan XT is live. Because Omnicell runs multiyear product cycles similar to iPhone, this launch matters. The last cycle ended a couple yrs ago. Today marks start of a new upgrade wave, which is important for bookings and backlog. Titan XT is the new automated system, and part of the story is OmniSphere, their cloud platform. It unifies pharmacy / nursing workflows, creates a connected medication network, and brings AI into inventory forecasting and task guidance. So this is big. They sit in a duopoly w Pyxis. However feedback for Pyxis is negative. As hospitals come up for renewal, they have a brand new unified offering against a lack luster competitive product. For $OMCL , looks like early feedback is strong. A system reported 70% time savings on cabinet restocking thanks to OmniSphere’s guided workflows. Investor lens: a new product cycle, shift to cloud intelligence, and platform that can keep compounding. Real step forward. __ $BDX $AAPL
0 · Reply
Estimize
Estimize Dec. 8 at 1:06 PM
Wall St is expecting 0.49 EPS for $OMCL Q4 [Reporting 02/05 BMO] http://www.estimize.com/intro/omcl?chart=historical&metric_name=eps&utm_co
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 2:50 PM
$OMCL looks like one of those under-the-radar setups with real legs. An expanding SaaS pipeline, a broader global push, and solid solvency are all pointing to growth potential — even with rising competition in the mix. Dive into the full breakdown here 👉 https://www.zacks.com/stock/news/2800097/reasons-to-add-omnicell-stock-to-your-portfolio-right-now?cid=sm-stocktwits-2-2800097-teaser-23600&ADID=SYND_STOCKTWITS_TWEET_2_2800097_TEASER_23600
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 1:51 PM
$OMCL soared 27.8% over the past year — what’s fueling the surge? 🚀 Omnicell's SaaS and Expert Services, global expansion plans, and strong liquidity and capital structure are driving growth 📈. The company boasts a Zacks Rank #2 (Buy) and a 38.7% earnings surprise average over the last four quarters. See what could drive OMCL higher 👉 https://www.zacks.com/stock/news/2800097/reasons-to-add-omnicell-stock-to-your-portfolio-right-now?cid=sm-stocktwits-2-2800097-body-23587&ADID=SYND_STOCKTWITS_TWEET_2_2800097_BODY_23587
0 · Reply
DoctorTy
DoctorTy Nov. 20 at 9:25 PM
$HIMS so now they xay $OMCL is better buy from hims. Any opinions
0 · Reply